Can Cannabis Reduce Reliance on Antipsychotics for Dementia? 

Antipsychotic medications are sometimes prescribed to manage severe agitation, aggression, or psychosis in people with dementia, but they carry serious risks, including sedation, falls, and an increased risk of stroke or death in older adults. Families and clinicians are increasingly looking for safer alternatives, and some have asked whether medical cannabis could play a role in reducing the need for antipsychotics. 

According to current NHS and NICE guidance, cannabis-based medicinal products (CBMPs) are not recommended for behavioural or psychological symptoms of dementia, and there is no strong evidence that they reduce reliance on antipsychotics. 

Understanding Antipsychotic Use in Dementia 

Antipsychotics, such as risperidone or haloperidol, may be prescribed when severe agitation or distress poses a risk to the person or others. However, NICE recommends they be used only for the shortest possible duration and under close clinical monitoring, as their risks often outweigh benefits for many patients. 

Non-drug interventions, such as behavioural support, sensory therapy, and environmental adjustments, are always preferred as first-line strategies. Interest in medical cannabis has grown partly because cannabinoids are thought to interact with brain systems involved in mood and behaviour, potentially offering gentler effects than traditional antipsychotics. 

What The Evidence Shows 

NICE guidance on Cannabis-based Medicinal Products (NG144) clearly states that cannabis-based medicines are not recommended for behavioural or psychological symptoms of dementia. The evidence is considered insufficient to demonstrate safety or effectiveness. 

The NHS echoes this position, explaining that cannabis is not an approved or routinely prescribed treatment for dementia and should be used only in research settings. 

According to the Alzheimer’s Society UK, most studies exploring cannabinoids such as THC and CBD have been small and short-term, often lasting only four to twelve weeks. While some suggest minor improvements in agitation or sleep, none have shown meaningful or sustained reductions in the use of antipsychotics or overall medication burden. 

Recent systematic reviews, including those from the Cochrane Dementia and Cognitive Improvement Group (2022), and ongoing UK trials sponsored by Alzheimer’s Research UK, support this conclusion. Evidence remains inconsistent, and CBMPs are still regarded as experimental therapies rather than established alternatives to antipsychotics. 

What Research Says About CBMPs And Antipsychotic Use 

Several small studies have explored whether cannabinoids like THC and CBD could reduce agitation or aggression in dementia, which might in turn lower the need for antipsychotic medication. 

• The STAND Trial (King’s College London, 2023–2025): This ongoing UK study investigates the safety and tolerability of CBD-dominant formulations in people with dementia-related agitation. Early reports suggest that cannabinoids are well tolerated but have not yet demonstrated significant or consistent symptom reduction compared with placebo (ISRCTN97163562). 

• Sativex Feasibility Study (2024, Frontiers in Aging Neuroscience): This study examined a balanced THC: CBD spray (Sativex) for agitation in Alzheimer’s disease. Results indicated minor improvements in agitation scores, but the effect was short-lived and not statistically significant in larger analyses (PMC12143470). 

In both studies, participants continued their usual medications, and there was no evidence that cannabis reduced the need for antipsychotics or other psychotropic drugs. 

Clinical Considerations and Safety 

Safety remains a key concern, especially in older adults with cognitive decline. Cannabis-based products can cause sedation, dizziness, and confusion, all of which may worsen frailty or increase fall risk. 

According to NHS and NICE, these potential harms outweigh any weak evidence of benefit. Moreover, most cannabinoid studies in dementia have involved small samples, inconsistent dosing, and short durations, all major limitations that prevent reliable conclusions about reducing reliance on antipsychotics. 

The Clinical Bottom Line 

• Cannabis-based medicinal products are not recommended for behavioural or psychological symptoms of dementia. 

• NICE and NHS restrict CBMPs to formal research trials only. 

• Current evidence does not support cannabis as a substitute or reduction strategy for antipsychotics. 

• Small pilot studies show inconsistent, short-term effects on agitation and anxiety. 

• Risks include confusion, sedation, dizziness, and falls, particularly in frail patients. 

• Families should prioritise non-drug approaches and seek clinical review before considering trial participation. 

What This Means in Practice 

At present, medical cannabis cannot be recommended as a way to reduce reliance on antipsychotic medication in dementia care. The best evidence-based strategies for managing behavioural symptoms remain person-centred approaches, environmental adjustments, and support for caregivers. 

About AlleviMed 

Organisations such as AlleviMed provide educational information about how UK eligibility for medical cannabis is assessed, helping families understand the legal and clinical frameworks surrounding CBMPs, but do not offer prescribing or treatment services. 

Takeaway 

Current evidence does not support cannabis as a safe or effective alternative to antipsychotic medication in dementia care. According to NHS, NICE, and the Alzheimer’s Society, cannabis-based medicinal products should only be used within carefully monitored clinical trials until stronger, long-term research demonstrates clear benefits and safety.